2023年限制性股票激励计划第二类限制性股票
Search documents
恩威医药股份有限公司
Shang Hai Zheng Quan Bao· 2025-10-29 21:49
Core Viewpoint - The company has adjusted the grant price and quantity of the second category of restricted stock in its 2023 incentive plan, which will not significantly impact its financial status or operational results [4][15][27]. Summary by Sections Incentive Plan Adjustments - The company held its third board meeting on October 29, 2025, where it approved the adjustment of the grant price for the second category of restricted stock to 13.48 yuan per share and agreed to void 21.8821 thousand shares that were granted but not vested [9][25]. - The adjustment was made following the completion of the 2024 annual profit distribution, which involved a cash dividend of 1.80 yuan per 10 shares, totaling approximately 18.19 million yuan [10][15]. Approval Process - The company followed necessary approval procedures for the 2023 restricted stock incentive plan, including meetings of the board and supervisory committee, and received independent opinions from legal and financial advisors [2][4][21]. - The plan was publicly disclosed, and no objections were raised during the internal announcement period [6][22]. Impact of Adjustments - The adjustments to the grant price and the voiding of certain shares will not materially affect the company's financial condition or management stability, and the management team will continue to fulfill its responsibilities [15][27]. - The voided shares accounted for approximately 0.2127% of the company's total share capital [26]. Legal Opinions - Legal opinions confirm that the adjustments and the conditions for vesting have been met in accordance with relevant regulations, ensuring compliance with the management and incentive plan guidelines [17][29].